Table 1 Key baseline characteristics from each CVOT
Trial/year of publication | Study drug/follow-up (y) | Participants (n) | Mean age years | Baseline HbA1c | Prior CVD (%) | Study funder |
|---|---|---|---|---|---|---|
DPP-4i | ||||||
 SAVOR-TIMI 53 | Saxagliptin | 16,492 | 65.0 | 8.0% | 78.6 | AstraZeneca |
 2013 | 2.1 |  |  | 64 mmol |  | Bristol-Myers |
 EXAMINE | Alogliptin | 5380 | 61.0 | 8.0% | 100 | Takeda |
 2013 | 1.5 |  |  | 64 mmol |  |  |
 TECOS | Sitagliptin | 14,6671 | 66.0 | 7.3% | 74 | Merck Sharp & |
 2015 | 2.8 |  |  | 56 mmol |  | Dohme |
 CARMELINA | Linagliptin | 6979 | 65.9 | 7.9% | 100 | Boehringer |
 2018 | 2.2 |  |  | 63 mmol |  | Ingelheim |
GLP-1RA | ||||||
 ELIXA | Lixisenatide | 6068 | 60 | 7.7% | 100 | Sanofi |
 2015 | 2.1 |  |  | 61 mmol |  |  |
 LEADER | Liraglutide | 9340 | 64.3 | 8.7% | 72.4 | Novo-Nordisk |
 2016 | 3.8 |  |  | 72 mmol |  |  |
 SUSTAIN-6 | Semaglutide | 3297 | 64.6 | 8.7% | 83.0 | Novo-Nordisk |
 2016 | 3.1 |  |  | 72 mmol |  |  |
 EXSCEL | Exenatide OW | 14,752 | 62.0 | 8.0% | 73.1 | Amylin Pharma- |
 2017 | 3.2 |  |  | 64 mmol |  | ceuticals |
 HARMONY | Albiglutide | 9463 | 64.0 | 8.7% | 100 | GlaxoSmithKline |
 2018 | 1.6 |  |  | 72 mmol |  |  |
 REWIND | Dulaglutide | 9901 | 66.2 | 7.2% | 31.4 | Boehringer/Lilly |
 2019 | 5.4 |  |  | 55 mmol |  |  |
 PIONEER 6 | Semaglutide O | 3183 | 66.0 | 8.2% | 84.7 | Novo-Nordisk |
 2019 | 1.3 |  |  | 66 mmol |  |  |
 AMPLITUDE-0 | Efpeglenatide | 4076 | 64.5 | 8.9% | 89.6 | Sanofi |
 2021 | 1.8 |  |  | 74 mmol |  |  |
SGLT-2i | ||||||
 EMPA-REG | Empagliflozin | 7021 | 63.2 | 8.1% | 100 | Boehringer/Lilly |
 2015 | 3.1 |  |  | 65 mmol |  |  |
 CANVAS | Canagliflozin | 10,142 | 63.2 | 8.2% | 72.2 | Janssen |
 2017 | 2.4 |  |  | 66 mmol |  |  |
 DECLARE | Dapagliflozin | 17,160 | 63.8 | 8.3% | 40.6 | AstraZeneca |
 2017 | 4.2 |  |  | 67 mmol |  |  |
 CREDENCE | Canagliflozin | 4401 | 63.0 | 8.3% | 50.4 | Janssen |
 2019 | 2.6 |  |  | 67 mmol |  |  |
 VERTIS-CV | Ertugliflozin | 8246 | 64.4 | 8.2% | 100 | Merck Sharp & |
 2020 | 3.0 |  |  | 66 mmol |  | Dohme |
 SCORED | Sotagliflozin | 10,584 | 69.0 | 8.3% | 48.6 | Sanofi/Lexicon |
 2021 | 1.4 |  |  | 67 mmol |  | Pharmaceuticals |